Introduction

RESEARCH ARTICLE
Metformin Down-regulates Endometrial Carcinoma Cell Secretion of IGF-1 and Expression of IGF-1R
Yu Zhang*, Meng-Xiong Li, Huan Wang, Zheng Zeng, Xiao-Mao Li* siRNA targeting IGF-1R on endometrial carcinoma (Shu et al., 2011) . In addition, endometrial carcinoma cells can synthesize and secrete IGF-I and IGF-II, which can integrate with their IGF-1R membrane receptor system and thereby cause continuous proliferation of tumor cells (Pavelic et al., 2007) .
Metformin is a biguanide, commonly used for treating type 2 diabetes mellitus, increases insulin sensitivity and improves glycemic control (Nathan., 2009; Nevadunsky et al., 2014) . Research shows that metformin can reduce the risks of some kinds of cancers including endometrial carcinoma (Goodwin et al., 2008; Pollak., 2010) and inhibit endometrial carcinoma cells growth by the mechanism that metformin acts as adenosine monophosphate-activated protein kinase (AMPK) agonist to inhibit mTOR phosphorylation (Xie et al., 2011; Arian et al., 2013) . Moreover, researchers think that metformin prevented lung cancer caused by smoking is based on metformin reducing IGF-1 and blood levels of insulin to suppress mTOR effect, while mTOR is a protein that promotes the growth of lung cancer cells (Leone et al., 2014) .
Whether metformin can regulate endometrial carcinoma cells secreting IGF-1 or expressing IGF-1R remains unknown. To answer this question, we tested the serum IGF-1 level in endometrial carcinoma patients before surgery and the medium of cells culture after treated with metformin. We also tested the IGF-1R in the human endometrial carcinoma paraffin sections and the change of IGF-1R expression, the signal pathway in vitro.
Materials and Methods
Patients and blood samples
12 cases of newly diagnosed as EC by pathology were grouped in the endometrial carcinoma (EC) group, and 12 cases of diagnosed as myoma or benign tumor of ovary without endometrial diseases were grouped in the control group during March 2013 to December 2013 at the Third Affiliated Hospital of Sun Yat-sen University. The average age was (51±13.65) years in the EC group and (47±10.23) years in the control group without significant difference. Diabetes and hormone taken in the past three months were excluded in all the cases. All EC cases were diagnosed as adenocarcinoma with high differentiated (5 cases), middle differentiated (5 cases) and low differentiated (2 cases) at the stagelafter surgery. The morning fasting venous blood 5ml of all the patients collected before surgery were allowed to clot for 2 h at room temperature and centrifuged for 20 min at 1000 rpm. Serum was removed and stored at -20℃ until assayed for the detection of IGF-1 value by ELISA . All patients provided written informed consent for participation in this study. The study protocol was approved by the Ethics Committees of the Third Affiliated Hospital of Sun Yat-sen University.
Human endometrium paraffin section
Human normal endometrium tissues and endometrial carcinoma tissues were obtained respectively from above patients. The tissues were paraffin-embedded, formalin-fixed and cut into 3μm sections for immunohistochemistry staining.
Endometrial carcinoma cell lines, chemicals and antibodies
Human endometrial carcinoma cell lines Ishikawa and JEC were provided by American Type Culture Collection (Manassas, USA). The cells were routinely cultured in Dulbecco's modification of Eagle's medium (Gibco, USA) supplied with 10% fetal calf serum (Hyclone, USA), at 37 °C in the humidified atmosphere of a 5% CO 2 incubation.
Metformin was obtained from Sigma (USA). Mouse/ Rat IGF-1 Immunoassay was obtained from Quantikine (USA). IGF-1Rβ Antibody #3027, Akt Antibody #4691, and Phospho-Akt (Ser473)#4060 were obtained from Cell Signaling Technology (USA), GAPDH Antibody was obtained from Santa Cruze (USA).
Immunoassay for IGF-1
Patients serum stored at -20℃ were assayed for the detection of IGF-1. Cells were cultured as above and allowed to proliferate until about 70-90% confluence. The serum containing medium was removed, cells were washed with PBS, and serum-free medium and 0mM or 10mM of Metformin were added. After 4 days, cells and medium was separated by centrifuging at 150g for 5 min. Protein degradation in the supernatant was prevented with protease inhibitors (0.2 mM phenylmethylsulfonyl fluoride, 1mM EDTA, and 0.5 mg/liter leupeptin). The conditioned medium was dialyzed overnight at 4°C using membrane tubing with a cutoff of 3500 molecular weight. Aliquots of dialyzed conditioned media were stored at -20°C until assayed.
The IGF-1 Immunoassay was operated to detect IGF-1 as described in the kit protocols.
Immunohistochemistry
Paraffin sections were incubated with IGF-1Rβ Antibody (1:100 dilution) according to the manufacturer's instructions. Slides were examined with a Leica microscope, scanned using an Aperio ScanScope instrument, and analyzed in ImageScope viewing software.
MTT assay
F o r 3 -( 4 , 5 -D i m e t h y l t h i a z o l -2 -y l ) -2 , 5-diphenyltetrazolium bromide (MTT) viability assay, 2~3×10 3 cells/well were plated in 96-well plates, cultured in the appropriate media, and viability was evaluated using MTT.
Colony assays
Fifty cells per well were plated on 96-well plates 24 h later, medium was replaced, and cells were incubated with chemicals at indicate concentration. Medium was replaced every day, and at day 14, the cells were fixed and stained using 0.5% crystal violet (Sigma).
Western blot analysis
Cells were harvested and total protein was extracted with RIPA buffer together with a protease inhibitor cocktail (Sigma). Lysates were resolved on 10% SDS-PAGE and immunoblotted with the indicated antibodies. Band intensities were quantified using Image J software.
Statistical analysis
The data were compared using the Student t test or analysis of variance (ANOVA), as appropriate. All tests were two-tailed, and p<0.05 was considered significant.
Results
Serum IGF-1 in endometrial carcinoma
Serum IGF-1 concentration was (159.88±102.32)ng/ ml in the endometrial carcinoma (EC) group, and was (167.92±112.26)ng/ml in the control group. There was no significant difference between the two groups (p﹥0.05, Figure 1 ).
IGF-1R highly expressed in endometrial carcinoma tissue
IGF-1R expressed abundantly in normal endometrial glands epithelial cells and endometrial carcinoma tissue, and most highly expressed in endometrial carcinoma tissue than in normal endometrial glands epithelial cells (Figure 2 ).
Metformin inhibited endometrial carcinoma cells Ishikawa and JEC viability
Effects of different concentration metformin on endometrial carcinoma cells Ishikawa and JEC growth were determined by MTT assay. Ishikawa cells were treated with metformin as indicated concentrations. Metformin attenuated the growth of Ishikawa and JEC cells (*p<0.05, **p<0.01, Figure 3) . And the clone assay DOI:http://dx.doi.org/10.7314/APJCP.2015.16.1.221 Metformin Down-regulates IGF-1 Secretion and IGF-1R Expression in Endometrial Cancer Cells also showed that clone numbers in the 10mM of metformin treated group was significantly less than that in the control group (*p<0.05, Figure 4) .
Metformin reduced IGF-1 concentration in culture medium and down-regulated the expression of IGF-1Rβ
Cells culture medium were collected and processed, and acid-alcohol was extracted to remove IGF-binding proteins as described under Materials and Methods, after which radioimmunoassays for IGF-1 were performed. The concentration of IGF-1 measured was lower in the group treated with 10mM of metformin than that in control group (*p<0.05, Figure 5A ).
And the intracellular β subunit of IGF-1R was significantly down-regulated when treated with 10mM of metformin than that with 0mM of metformin, resulting in lowering the ratio of p-AKT/AKT (*p<0.05, Figure 5B ).
Discussion
IGF-1 is a polypeptide of 70 amino acids, mainly synthesized by the liver, and local organizations such as endometrium also secrete IGF-1 through autocrine and paracrine. And human serum IGF-1 level decrease by age and change by the phase of endometrium (Zhou et al., 1994) . Studies demonstrate that IGF-1 is associated with the cancer development, progress and prognosis (Creighton et al., 2008; Torng et al., 2008) , but some studies show no change (Lukanov et al., 2008; Lacey et al., 2004; Weiderpass et al., 2003) or decrease (Gunter et al., 2008 ) of serum IGF-1 level in endometrial carcinoma cases. In our study, serum IGF-1 level in the EC group was also comparable to that in the control group (Figure 1) . So, till now serum IGF-1 can not be the serum predictor for endometrial carcinoma. But IGF-1 can be produced by the uterus endometrial stromal cells, regulating cell proliferation and differentiation in autocrine and paracrine manner (Haining et al., 1991) . Moreover, endometrial carcinoma cells can synthesize and secrete IGF-I and IGF-II, which can integrate with their IGF-1R membrane receptor and cause continuous proliferation of the tumor cells (Pavelie et al., 2007; Sarkissyan et al., 2014) . And we also verified that high expression of GLP-1R in the EC tissue than that in the normal endometrial tissue ( Figure  2 ). So local high IGF-1 level around the endometrial carcinoma cells matching with high expression of IGF-1R will promotes EC growth.
The fact of that metformin can inhibit cancer cells growth in vitro is accepted wildly, and the mechanism is associated with that metformin acts as AMPK agonist to inhibit mTOR phosphorylation (Zhou et al., 2001; Shaw et al., 2005; Xu et al., 2014) , and that metformin can reduce insulin/insulin like growth factor signaling and suppress the PI-3K/Akt/mTOR axis (Luo et al., 2010; Matin et al., 2010) . Metformin inhibits EC cells growth just as the results of MTT assay and clones formation in our study. Next, we observed the IGF-1 level in the medium of cells culture, the change of IGF-1R expression and its download signal after treated with metformin to testify whether metformin regulates IGF-1 level around the EC cells and IGF-1R expression to inhibit EC cells growth.
Growth factors are polypeptides that act by autocrine, paracrine, and endocrine pathways to regulate cell proliferation and death (Goustin et al., 1986) . When growth factors like epidermal growth factor (EGF), transforming growth factor-a (TGF-a), and IGF-1 binds to its specific receptor, an intracellular signal cascade is initiated, resulting in activation of gene transcription, protein synthesis and mitosis (Derynck et al., 1987) . And studies show that these growth factors including IGF-1 are potentially important in the development of endometrial carcinoma (Lelle et al., 1993; Pearl et al., 1993) . And IGF-1 is demonstrated in endometrial cancer cell lines by IGF-1 RIA (Eugenio et al., 1999) . Our data show IGF-1 secreted by endometrial cancer cell lines of Ishikawa and JEC can be detected in the culture, and the concentration of IGF-1 was lower in the group treated with 10mM of Metformin than that in the control group ( Figure 5A ). As we know Metformin acts as AMPK activator to decrease protein synthesis (Salani et al., 2014) , and the production of IGF-1 may be included. The IGF-1R is composed of extracellular α subunit and intracellular β subunit, which covalent bonds forming tyrosine kinase receptor. Its activation induces the phospharylation of downstream tyrosine residues and itself or transmits growth signal from extracellular to nucleus through PI-3K/Akt/mTOR and Ras/Raf/Erk pathways (Casamassima et al., 1998) . In our study, we detected intracellular β subunit of IGF-1R by western blot, and the intracellularβsubunit of IGF-1R was significantly down-regulated when treated with 10mM of metformin than that with 0mM of metformin, resulting in lowering the ratio of p-AKT/AKT (P < 0.05, Figure.5B ). Other studies has also shown that metformin decrease IGF-1R complex of trastuzumab-resistant breast cancer cells (Liu et al., 2011) and suggested that metformin disrupts crosstalk between insulin/ IGF-1R and G protein-coupled receptors in pancreatic cancer cells (Kisfalvi et al., 2009; Rozengurt et al., 2010; Markowska et al., 2014 ) .
In summary, metformin can reduce endometrial carcinoma cell lines of Ishikawa and JEC secreting IGF-1 and expressing IGF-1R to deactivate downstream signaling involving the PI-3K/Akt pathway to inhibit endometrial carcinoma cell growth. Further detailed analyses and clinical trials will be necessary to identify the specific molecular mechanisms, and to determine whether metformin would have similar effects in vivo. We will explore this mechanism in patients or models of endometrial carcinoma as well in next study.
